Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension

Liver Transplantation

Volumn 15, Issue 1, 2009, Pages 30-36

  Gough, Michael S ^a   White, R James ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL; UNIPROST;

ADULT; ARTICLE; CATHETERIZATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CHOICE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HEMODYNAMIC PARAMETERS; HUMAN; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECURRENT DISEASE; REOPERATION; SAFETY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; COHORT STUDIES; FEMALE; HEART CATHETERIZATION; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PIPERAZINES; PURINES; RETROSPECTIVE STUDIES; SULFONES; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 64049084092     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21533     Document Type: Article

References (38)

1. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(suppl):S5-S12.
2. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(suppl):S40-S47.
3. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB, et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997;3: 494-500.
4. Taura P, Garcia-Valdecasas JC, Beltran J, Izquierdo E, Navasa M, Sala-Blanch J, et al. Moderate primary pulmonary hypertension in patients undergoing liver transplantation. Anesth Analg 1996;83:675-680.
5. Castro M, Krowka MJ, Schroeder DR, Beck KC, Plevak DJ, Rettke SR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996;71:543-551.
6. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006;44:1502-1510.
7. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:443-450.
8. Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004;10: 174-182.
9. Torregrosa M, Genesca J, Gonzalez A, Evangelista A, Mora A, Margarit C, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation 2001;71: 572-574.
10. Blendis L, Wong F. Portopulmonary hypertension: an increasingly important complication of cirrhosis. Gastroenterology 2003;125:622-624.
11. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997;63:604-606.
12. Plotkin JS, Kuo PC, Rubin LJ, Gaine S, Howell CD, Laurin J, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998;65:457-459.
13. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
14. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157.
15. Halank M, Miehlke S, Hoeffken G, Schmeisser A, Schulze M, Strasser RH. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 2004;77:1775-1776.
16. Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 2005; 128:164-168.
17. Hinterhuber L, Graziadei IW, Kahler CM, Jaschke W, Vogel W. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2004;2: 1039-1042.
18. Molnar C, Alber H, Colleselli D, Vogel W, Kahler CM, Molnar C, et al. Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis. Wien Klin Wochenschr 2004;116:627-630.
19. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:502-508.
20. Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007;30:1096-10102.
21. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl 2004;10:945-950.
22. Chua R, Keogh A, Miyashita M, Chua R, Keogh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 2005;24:498-500.
23. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006;28:563-567.
24. White RJ, Lansing K, Bozorgzadeh A. Sildenafil in portopulmonary hypertension: a preliminary single-center report. Am J Respir Crit Care Med 2004;169:A177.
25. Gough MS, White RJ. Sildenafil reduces pulmonary vascular resistance allowing for orthotopic liver transplantation in patients with portopulmonary hypertension: an open-label single-center report. Chest 2006;130:250S.
26. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB, and ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004;24:861-880.
27. Krowka MJ, Plevak D. The distinct concepts and implications of hepatopulmonary syndrome and portopulmonary hypertension [comment]. Crit Care Med 2005;33:470.
28. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003;167: 1139-1141.
29. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42:158-164.
30. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003;37:401-409.
31. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005;11:1107-1111.
32. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641-648.
33. Zhang M, Luo B, Chen SJ, Abrams GA, Fallon MB. Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. Am J Physiol 1999;277(pt 1):G944-G952.
34. Luo B, Liu L, Tang L, Zhang J, Ling Y, Fallon MB. Et-1 and tnf-alpha in hps: analysis in prehepatic portal hypertension and biliary and nonbiliary cirrhosis in rats. Am J Physiol Gastrointest Liver Physiol 2004;286:G294-G303.
35. Ling Y, Zhang J, Luo B, Song D, Liu L, Tang L, et al. The role of endothelin-1 and the endothelin b receptor in the pathogenesis of hepatopulmonary syndrome in the rat. Hepatology 2004;39:1593-15602.
36. Deibert P, Schumacher YO, Ruecker G, Opitz OG, Blum HE, Rossle M, et al. Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver-results of a pilot study. Aliment Pharmacol Ther 2006;23:121-128.
37. Finley DS, Lugo B, Ridgway J, Teng W, Imagawa DK. Fatal variceal rupture after sildenafil use: report of a case. Curr Surg 2005;62:55-56.
38. Kim WR, Krowka MJ, Plevak DJ, Lee J, Rettke SR, Frantz RP, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000;6:453-458.